Compound Edaravone Injection for Acute Ischemic Stroke
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2015-07-03
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT01929096
- Locations
- 🇨🇳
Central Hospital of Baotou, Baotou, Inner Mongolia, China
🇨🇳The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
🇨🇳Navy General Hospital of The Chinese PLA, Beijing, Beijing, China
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT01909856
- Locations
- 🇨🇳
Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT01893151
- Locations
- 🇨🇳
Third Affiliated Hospital Of Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT01847118
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01772732
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study of Iguratimod in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1759
- Registration Number
- NCT01554917
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 910
- Registration Number
- NCT01548001
- Locations
- 🇨🇳
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT01531790
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT01469910
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
- Conditions
- Influenza A Virus InfectionInfluenza B Virus Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 298
- Registration Number
- NCT01459081
- Locations
- 🇨🇳
The Third Xiangya Hospital Of Central South University, Changsha, China
🇨🇳The First People's Hospital of Hangzhou, Hangzhou, China
🇨🇳The Affiliated Hospital of Inner Mongolia Medical College, Huhehaote, China